42%
Oncology Phase III
Faster Enrollment for Global Solid Tumor Study

A mid-size biotech was 6 months behind on enrollment for a Phase III non-small cell lung cancer trial. TPRA rescued the study and completed enrollment 42% faster than original projections.

Read the full case study
4x
CNS Rare Disease
Quadrupled Referral Volume for Neurology Trial

After replacing an underperforming vendor, TPRA delivered 4x the qualified referrals within 90 days for a rare neurological disorder study, meeting enrollment targets ahead of schedule.

Read the full case study
$1.2M
Cardiology Phase II
Cost Savings from Early Completion

TPRA's pre-screening reduced screen failures by 38% and completed enrollment 3 months early for a heart failure trial, saving the sponsor over $1.2M in operational costs.

Read the full case study
89%
Rare Disease Phase II
Screen Pass Rate for Orphan Drug Study

Using medical pre-screening and patient education, TPRA achieved an 89% screen pass rate for a complex ultra-rare metabolic disorder trial with highly restrictive inclusion criteria.

Read the full case study
18
Women's Health Global
Countries Activated in 6 Months

Large pharma needed global recruitment support for an endometriosis study. TPRA activated recruitment in 18 countries across 4 continents within 6 months, delivering consistent quality worldwide.

Read the full case study
6 wks
Psychiatry Rescue
Ahead of Schedule After Rescue

A depression study was failing with only 30% enrollment complete at month 10. TPRA took over, implemented targeted digital campaigns, and completed enrollment 6 weeks ahead of the revised timeline.

Read the full case study
95%
Autoimmune Phase III
Retention Rate Through Study Completion

TPRA's patient engagement program kept 95% of enrolled patients in a 12-month rheumatoid arthritis study, significantly exceeding industry benchmarks and sponsor expectations.

Read the full case study
247
Diabetes Phase II
Patients Enrolled in 8 Months

Type 2 diabetes trial needed 200 patients across 25 US sites. TPRA exceeded the target by enrolling 247 qualified patients in just 8 months using multi-channel recruitment and site optimization.

Read the full case study
63%
Pediatric Rare
Reduction in Screen Failure Rate

A pediatric rare disease study had a 45% screen failure rate. TPRA implemented enhanced pre-screening protocols and genetic testing coordination, reducing failures to just 17% (63% improvement).

Read the full case study

Aggregate Results Across All Studies

Combined performance metrics from TPRA-supported trials

32%
Faster Enrollment
18K+
Patients Enrolled
84%
Avg Screen Pass Rate
92%
On-Time Completion

Ready to Write Your Success Story?

Let's discuss how TPRA can help you exceed your enrollment goals. Get a free consultation and enrollment forecast.